Press Release

Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India

Celebrating 40 Years in Malaysia

Read More

Earnings Call

Webcast – Q1 FY23 Earnings call

Press Release

Q1 FY23 Financial Press Release

Financial Results

Q1 FY23 Financial Results

COVID-19 Response

We are committed to ensure uninterrupted supply of medicines to support the Covid-19 pandemic response

The Sun Story

Watch the inspiring growth story of Sun – from humble beginnings in 1983 with just 2 employees and 5 psychiatry products to becoming the 4th largest global generic pharmaceutical company, selling over 2000 products in over 100 countries.

Sun Pharma on Twitter

Find out more

Innovation

Science is at the heart of Sun Pharma. Our scientists work closely with doctors, patients, and business development teams, to generate innovative concepts and ideas to harness market needs and synergies across therapeutic areas.

Quality

Our vision is to globalize, harmonize and simplify GxP processes to achieve a sustainable quality culture.

Careers

We hire exceptionally talented individuals, and ensure they are nurtured professionally. Our multi-dimensional work environment offers high growth opportunities through challenging roles with clear responsibilities.

Responsibility

Our CSR efforts are focused on serving and helping needy and underprivileged communities. Our priority areas include: health, education, drinking water and sanitation.

Sun Pharma offers a program for individuals who want to disclose violations of US FDA requirements related to facilities or products owned or operated by Ranbaxy prior to Sun Pharma acquisition of Ranbaxy. Continue

Top